Kalipoz Prolongatum

Potassium Chloride, the active ingredient in Kalipoz Prolongatum, is an electrolyte supplement presented as an oral dosage form for oral use. It treats hypokalemia and potassium deficiency by restoring normal potassium levels in patients who require potassium repletion.

GNH USA supplies Kalipoz Prolongatum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Originating from the European Union, the product meets stringent quality and regulatory standards, enabling reliable global distribution today for healthcare providers.

Kalipoz Prolongatum, an oral potassium chloride supplement, is used to correct electrolyte imbalances related to low potassium levels.

- Hypokalemia: restores serum potassium to the normal range, reducing the risk of cardiac arrhythmias. - Potassium deficiency: replenishes intracellular potassium stores, supporting normal muscle and nerve function. - Diuretic‑induced potassium loss: compensates for potassium depletion caused by loop or thiazide diuretics.

Potassium chloride may cause a range of adverse reactions, from mild gastrointestinal discomfort to serious electrolyte disturbances.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Abdominal discomfort: cramping or pain in the stomach area. - Constipation: reduced bowel movements. - Diarrhea: loose stools, especially with higher doses. - Taste alteration: metallic or salty taste in the mouth. - Hyperkalemia (mild): slight elevation of serum potassium.

Serious or Rare Side Effects: - Severe hyperkalemia: marked increase in serum potassium that can cause cardiac arrhythmias. - Cardiac arrest: life‑threatening heart rhythm disturbance. - Anaphylactic reaction: rare severe allergic response. - Muscle weakness: due to electrolyte imbalance. - Respiratory distress: in extreme cases of hyperkalemia.

When using Kalipoz Prolongatum, clinicians should observe several safety measures.

- Baseline assessment: check serum potassium and renal function before initiating therapy. - Monitoring: regularly measure potassium levels during treatment. - Renal impairment: adjust dose or avoid use in patients with severe kidney disease. - Hyperkalemia risk: discontinue if serum potassium exceeds recommended limits. - Concomitant drugs: use caution with ACE inhibitors, ARBs, or potassium‑sparing diuretics. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Potassium chloride can interact with several medications, affecting potassium balance.

Major Interactions (Avoid): - ACE inhibitors: may cause dangerous hyperkalemia. - Angiotensin II receptor blockers (ARBs): increase risk of elevated potassium. - Potassium‑sparing diuretics (e.g., spironolactone): can lead to severe hyperkalemia. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may impair renal potassium excretion. - Trimethoprim: reduces potassium clearance, raising serum levels.

Moderate Interactions (Monitor Closely): - Digoxin: high potassium can reduce digoxin toxicity. - Beta‑blockers: may mask symptoms of hyperkalemia. - Lithium: potassium levels influence lithium reabsorption. - Certain antibiotics (e.g., penicillamine): can affect potassium handling.